A randomized phase 3 trial of Alimta (pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer.

Trial Profile

A randomized phase 3 trial of Alimta (pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2011

At a glance

  • Drugs Carboplatin; Etoposide; Pemetrexed
  • Indications Small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GALES
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Dec 2011 Biomarker analysis results published in Annals of Oncology.
    • 27 Aug 2009 Interim analysis results have been reported in the Journal of Clinical Oncology.
    • 12 Nov 2008 Status changed from discontinued to completed, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top